Header Logo

Connection

FRITZ SEDLAZECK to Immunotherapy, Adoptive

Back to Details
This is a "connection" page, showing publications FRITZ SEDLAZECK has written about Immunotherapy, Adoptive.
FRITZ SEDLAZECK
Connection Strength
0.125
Immunotherapy, Adoptive
  1. Investigation of product-derived lymphoma following infusion of piggyBac-modified CD19 chimeric antigen receptor T cells. Blood. 2021 10 21; 138(16):1391-1405.
    View in: PubMed
    Score: 0.125
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.